{"id":792791,"date":"2024-12-05T09:05:18","date_gmt":"2024-12-05T14:05:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\/"},"modified":"2024-12-05T09:05:18","modified_gmt":"2024-12-05T14:05:18","slug":"iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\/","title":{"rendered":"ISS Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan and Dr. William M. Mitchell"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>ISS Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan and Dr. William M. Mitchell<\/b><\/p>\n<p class=\"bwalignc\"><i>ISS Finds That Activist Group\u2019s Plan is \u201cLimited\u201d and Does Not Justify Control of the Board<\/i><\/p>\n<p class=\"bwalignc\"><i>ISS Notes Activist Group Nominee Robert L. Chioini \u201cDoes Not Appear to Be an Appropriate Choice for the AIM Board\u201d Given His Track Record at Rockwell Medical and Ties to Securities Law Felons<\/i><\/p>\n<p class=\"bwalignc\"><i>ISS Also Recommends Against Election of Activist Group Nominee Todd A. Deutsch<\/i><\/p>\n<p class=\"bwalignc\"><i>AIM Highlights $15 Million+ Investment Partnership Between Activist Group Nominees Ted Kellner and Paul Sweeney \u2013 Meaning They Are Not Independent of One Another<\/i><\/p>\n<p class=\"bwalignc\"><i>Company Urges Shareholders to Safeguard AIM by Voting \u201cFOR\u201d ALL Four of the Board\u2019s Incumbent Candidates on the <b><span class=\"bwuline\">WHITE<\/span><\/b> Universal Proxy Card and Discarding Any Proxy Materials Received from the Activist Group<\/i><\/p>\n<p>OCALA, Fla.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAIM ImmunoTech Inc. (NYSE American: AIM) (\u201cAIM\u201d or the \u201cCompany\u201d) today announced that independent proxy advisory firm Institutional Shareholder Services Inc. (\u201cISS\u201d) has recommended that shareholders vote \u201cFOR\u201d Company nominees Nancy K. Bryan and Dr. William M. Mitchell at the upcoming 2024 Annual Meeting of Stockholders (the \u201cAnnual Meeting\u201d), presently scheduled for December 17, 2024.<\/p>\n<p>\nIn reaching its recommendation against giving the activist investors\u2019 (the \u201cActivist Group\u201d) nominees control of the AIM Board of Directors (the \u201cBoard\u201d), ISS noted the following: <sup>1<\/sup><\/p>\n<ul class=\"bwlistdisc\">\n<li><b><i>\u201c\u2026the [Activist Group] plan is limited, only one of its nominees has relevant life sciences expertise, and half of its slate has apparent ties to individuals with concerning backgrounds.\u201d<\/i><\/b><\/li>\n<\/ul>\n<p>\nISS flags specific concerns with Activist Group nominee Robert L. Chioini and recommends shareholders vote AGAINST Mr. Chioini and fellow nominee Todd A. Deutsch:<\/p>\n<ul class=\"bwlistdisc\">\n<li><b><i>\u201cGiven Chioini&#8217;s track record at [Rockwell Medical] and his connections to [securities law felons] Tudor and Xirinachs, he does not appear to be an appropriate choice for the AIM [B]oard.\u201d<\/i><\/b><\/li>\n<\/ul>\n<p>\nFinally, ISS concludes that a solution along the lines of AIM\u2019s settlement proposal to the Activist Group represents a reasonable compromise:<\/p>\n<ul class=\"bwlistdisc\">\n<li><b><i>\u201cPerhaps the [C]ompany&#8217;s suggestion that the [B]oard be expanded with two or more additional independent directors mutually agreed by both sides would be the most logical solution.\u201d<\/i><\/b><\/li>\n<\/ul>\n<p>\nUnfortunately, the Activist Group has consistently demanded upwards of $8 million in expense reimbursement for prior failed litigation in order to consummate a settlement agreement.<\/p>\n<p>\nAIM notes that ISS did <i>not <\/i>appear to take into account the extensive financial interconnections between Ted D. Kellner and Paul W. Sweeney that the Company had recently <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Faimimmunotech.s3.us-west-1.amazonaws.com%2FThe%2BActivist%2BGroup%25E2%2580%2599s%2BSlate%2Bis%2Bthe%2BWrong%2BChoice%2Bfor%2BAIM%2BShareholders%2B%28December%2B2024%29.pdf&amp;esheet=54162315&amp;newsitemid=20241205465233&amp;lan=en-US&amp;anchor=highlighted&amp;index=1&amp;md5=9cfcb6d3bfd6f72974f4ab34d5bb09ae\">highlighted<\/a>. It is essential that investors are aware of the following:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nIn a glowing testimonial, <b>Mr. Kellner proclaims himself as the \u201clargest investor in almost every deal\u201d<\/b><b><sup>2<\/sup> put together by PS Capital Partners<\/b>, the private equity firm co-founded by Mr. Sweeney.<\/p>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nThe <b>fact that Mr. Kellner is apparently the largest investor in almost all of Mr. Sweeney\u2019s deals is <i>not <\/i>disclosed in the Activist Group\u2019s definitive proxy statement<\/b>,<sup>3<\/sup> preventing the Board and investors from making an informed decision about the Activist Group\u2019s nominees.<\/p>\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\nWe believe this reflects the same pattern seen from the Activist Group in prior years \u2013 <b>repeated attempts to obfuscate the group\u2019s interconnections and mislead AIM shareholders<\/b>.<\/p>\n<\/li>\n<\/ul>\n<p>\nDr. William M. Mitchell, Chairman of the Board, stated:<\/p>\n<p><i>\u201cWe are grateful ISS recommended in favor of electing two of our nominees, Nancy Bryan and myself, while highlighting our leadership experience and expertise in the life sciences industry. In not recommending turning over control of the Board to the Activist Group, ISS notes that the Activist Group\u2019s proposed plan for AIM is not sufficiently detailed and also takes into account the Activist Group\u2019s connections to securities law felons.<\/i><\/p>\n<p><i>\u201cHowever, we disagree with several of ISS\u2019s conclusions. First, AIM\u2019s ability to garner government funding and industry grants for clinical trials is beneficial because it allows the Company to avoid paying out of pocket for these trials. That third parties such as Merck and AstraZeneca are willing to fund these clinical trials demonstrates that major industry organizations recognize Ampligen\u2019s potential.<\/i><\/p>\n<p><i>\u201cSecond, both Tom Equels and Stewart Appelrouth bring expertise to the Board that is critical to the success of AIM, and we strongly urge shareholders to vote for their reelection. As CEO, Mr. Equels has extensive familiarity with Ampligen. He was responsible for the focus on pancreatic ductal cancer and the initiation of the first clinical trial development in the Netherlands with no clinical trial cost to AIM. Definitive clinical trials are well underway and indicate the likelihood of proven efficacy in this high value, devastating cancer with limited treatment options. Moreover, Mr. Equels is an inventor of record for several patents assigned to AIM. These include (1) the combination of Ampligen with immune checkpoint inhibitors for the treatment of challenging cancers; (2) a novel method for the treatment of Chronic Fatigue Syndrome; and (3) methods and compositions for treating debilitating endometriosis, which affects a significant number of premenopausal women. Mr. Appelrouth is a nationally recognized forensic CPA who brings valuable financial and regulatory expertise to the boardroom. He serves as the essential function of financial expert for AIM\u2019s audit committee. Both have helped drive the Company\u2019s shift in focus towards high-value indications.<\/i><\/p>\n<p><i>\u201cWe firmly believe the Board has the right experience and backgrounds to continue overseeing its strategy to create long-term value for patients and shareholders. Our Board members remain committed to supporting clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space, to unlock the potential of Ampligen and deliver significant long-term value for all shareholders.<\/i><\/p>\n<p><i>\u201cWe look forward to continuing to engage with AIM shareholders in advance of the Annual Meeting.\u201d<\/i><\/p>\n<p>\nAIM encourages shareholders to vote \u201c<b>FOR<\/b>\u201d ALL four of the Board\u2019s incumbent candidates \u2013 <b>Stewart L. Appelrouth<\/b>, <b>Nancy K. Bryan<\/b>, <b>Thomas K. Equels<\/b> and <b>Dr. William M. Mitchell<\/b> \u2013 in connection with the Annual Meeting, on the <b><span class=\"bwuline\">WHITE<\/span><\/b> universal proxy card.<\/p>\n<p>\nFor more information on how to vote, visit: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.SafeguardAIM.com&amp;esheet=54162315&amp;newsitemid=20241205465233&amp;lan=en-US&amp;anchor=www.SafeguardAIM.com&amp;index=2&amp;md5=b8e4adec98054ad6eb02e279d90b74e3\">www.SafeguardAIM.com<\/a>.<\/p>\n<p class=\"bwalignc\">\n***<\/p>\n<p><b>About AIM ImmunoTech Inc.<\/b><\/p>\n<p>\nAIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company\u2019s lead product is a first-in-class investigational drug called Ampligen<sup>\u00ae<\/sup> (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.<\/p>\n<p>\nFor more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DNJE1OVmM3vXX32UkYGXxM6a6gkfQ_2DnYLGx5Klimcg0SIUEXl6aHRMSXtvH1CLTDWpH3rTZCiAufpi5t6p-9p0EjO4NkMNsbEmaTpDEswzNvszJH-aM8EOVRVV888nSbRAC2vgyABZdN43GQxbKWBWzq50NJCOKM_txPvOidUGSpZiA6wkCZ9XafYPMf374-f3xMdS5d6mvfaEOh-SJLIKjWpDnDC4MU6UbdbumhiM%3D&amp;esheet=54162315&amp;newsitemid=20241205465233&amp;lan=en-US&amp;anchor=aimimmuno.com&amp;index=3&amp;md5=bf4975e6124dd96479de118812e136e3\">aimimmuno.com<\/a> and connect with the Company on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D92BdXKffHdlioqhz-03Fs1SCxSuJ_YoMC7zzeRUzUmKpf7AaDkBpYBTNmSb7rglz-sAOfhSiDQnjcDs7oVHDxRh8XwYe4c-pmYVskUuuh8bvCHDBFGX4xLNz1zK4hU7V6GLIwLCNHTpTc3UrFO1v2vYwW81LULNmHnyAioz-3x4z48aJsAJoIQ8tFBHNuatL8y9ibmHX8n4XrDgC1-b7mA%3D%3D&amp;esheet=54162315&amp;newsitemid=20241205465233&amp;lan=en-US&amp;anchor=X&amp;index=4&amp;md5=8ef7efc556b53a19f67c750cf7257c9d\">X<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DsH78EHx_UKrXcfI2LUu9Z-lJSSOS6QZWbFZ_oXe2paNrGUii0hZrZS-O8LpzT9xas82flUWriJU1CELIbJRK3auVrVaEDkTliYmOtiiS1roLBVcUKuFc-VDV3F9CDOzZtpr5OP-EhbFK6rWaduz5-fjevnRRIXmlvFUqnlpPBQjjsV2btrpz-PCrlg5pZboGQ-kTvRf26jHEl590OiKDSQJFO18V8Jv64H91CHtkRYqC2k-setqZttauwo7FW8mY&amp;esheet=54162315&amp;newsitemid=20241205465233&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=5&amp;md5=4ada1385fb9f542195c0a19e57285a49\">LinkedIn<\/a>, and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DJeXN46_2i1JvodZ_6kBxk9GunKEzpFGqa2Zmmrlzfr4Raz091cyw-p8SHz23j3lH6K5xQJYu-rKrBzzt7EpdtatCcPFQhMr5aS_RpmlQP2HbCicT2yIIM0Ye7C_X2GrDyMo2HtaxnWuXkNHO4tixq669IbfdjHIGzxPmlgv2n2HYlb4VgXnlnYvcMdFgr2LS-P21zmT51kPJv3oeCw7PI4dx2Oaf5iH_8SeuZPb3MuZi95OBx6XpmsSUQjgSPirK&amp;esheet=54162315&amp;newsitemid=20241205465233&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=bff17780444a0e2908d57c92dd1e8293\">Facebook<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the \u201cPSLRA\u201d). Words such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccontinue,\u201d \u201cbelieve,\u201d \u201cpotential,\u201d \u201cupcoming\u201d and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date does not guarantee that Ampligen will be approved as a treatment or therapy for any diseases or conditions. The Company urges investors to consider specifically the various risk factors identified in its most recent Annual Report on Form 10-K, and any risk factors or cautionary statements included in any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K, filed with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.<\/p>\n<p><b>Important Additional Information<\/b><\/p>\n<p>\nThe Company, its directors and executive officers, Peter W. Rodino, III and Robert Dickey, IV, are deemed to be \u201cparticipants\u201d (as defined in Section 14(a) of the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from the Company\u2019s stockholders in connection with the Annual Meeting. The Company filed its definitive proxy statement (the \u201cDefinitive Proxy Statement\u201d) and a <b>WHITE <\/b>universal proxy card with the SEC on November 4, 2024 in connection with such solicitation of proxies from the Company\u2019s stockholders. <b>STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH DEFINITIVE PROXY STATEMENT, ACCOMPANYING WHITE UNIVERSAL PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING.<\/b> The Definitive Proxy Statement contains information regarding the identity of the participants, and their direct and indirect interests, by security holdings or otherwise, in the Company\u2019s securities and can be found in the section titled \u201cPrincipal Stockholders\u201d of the Definitive Proxy Statement and available <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sec.gov%2FArchives%2Fedgar%2Fdata%2F946644%2F000149315224043423%2Fformdefc14a.htm%23%3A%7E%3Atext%3Dour%2520common%2520stock.-%2CPRINCIPAL%2520STOCKHOLDERS%2C-The%2520following%2520table&amp;esheet=54162315&amp;newsitemid=20241205465233&amp;lan=en-US&amp;anchor=here&amp;index=7&amp;md5=de4274d83de12c688daca5898b9bf472\">here<\/a>. Information regarding subsequent changes to their holdings of the Company\u2019s securities can be found in the SEC filings on Forms 3, 4, and 5, which are available on the Company\u2019s website available <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Faimimmuno.com%2Fsec-filings%2F&amp;esheet=54162315&amp;newsitemid=20241205465233&amp;lan=en-US&amp;anchor=here&amp;index=8&amp;md5=af12dcab65d5044e3d757ee7da6611a7\">here<\/a> or through the SEC\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=54162315&amp;newsitemid=20241205465233&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=451336a9dbd3c0982c09db7ec3983a38\">www.sec.gov<\/a>. Stockholders will be able to obtain the Definitive Proxy Statement, any amendments or supplements thereto and other documents filed by the Company with the SEC at no charge at the SEC\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=54162315&amp;newsitemid=20241205465233&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=10&amp;md5=006c3944872b02317050dc7d77207d7e\">www.sec.gov<\/a>. Copies will also be available at no charge at the Company\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Faimimmuno.com%2Fsec-filings%2F&amp;esheet=54162315&amp;newsitemid=20241205465233&amp;lan=en-US&amp;anchor=https%3A%2F%2Faimimmuno.com%2Fsec-filings%2F&amp;index=11&amp;md5=5438bfd5e96b490afd61e407712d8206\">https:\/\/aimimmuno.com\/sec-filings\/<\/a>.<\/p>\n<p><sup>1<\/sup> Permission to quote ISS neither sought nor obtained. Emphasis added.<br \/>\n<br \/><sup>2<\/sup><i>See<\/i> PS Capital Partners\u2019 Testimonials Page available at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fpscapitalpartners.com%2Ftestimonials%2F&amp;esheet=54162315&amp;newsitemid=20241205465233&amp;lan=en-US&amp;anchor=https%3A%2F%2Fpscapitalpartners.com%2Ftestimonials%2F&amp;index=12&amp;md5=9f8271746ecb234fb36b27d7a97a1c74\">https:\/\/pscapitalpartners.com\/testimonials\/<\/a>.<br \/>\n<br \/><sup>3<\/sup><i>See<\/i> Definitive Proxy Statement filed by the Activist Group with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d) on November 6, 2024.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241205465233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20241205465233\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20241205465233\/en\/<\/a><\/span><\/p>\n<p><b>Investor Contact:<br \/>\n<\/b><br \/>JTC Team, LLC<br \/>\n<br \/>Jenene Thomas<br \/>\n<br \/>908-824-0775<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:AIM@jtcir.com\">AIM@jtcir.com<br \/>\n<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<\/b><br \/>Longacre Square Partners<br \/>\n<br \/>Joe Germani \/ Miller Winston<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:AIM@longacresquare.com\">AIM@longacresquare.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Florida United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Finance Clinical Trials Professional Services Biotechnology Pharmaceutical Health Science Oncology Other Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>ISS Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan and Dr. William M. Mitchell ISS Finds That Activist Group\u2019s Plan is \u201cLimited\u201d and Does Not Justify Control of the Board ISS Notes Activist Group Nominee Robert L. Chioini \u201cDoes Not Appear to Be an Appropriate Choice for the AIM Board\u201d Given His Track Record at Rockwell Medical and Ties to Securities Law Felons ISS Also Recommends Against Election of Activist Group Nominee Todd A. Deutsch AIM Highlights $15 Million+ Investment Partnership Between Activist Group Nominees Ted Kellner and Paul Sweeney \u2013 Meaning They Are Not Independent of One Another Company Urges Shareholders to Safeguard AIM by Voting \u201cFOR\u201d ALL Four of the Board\u2019s Incumbent Candidates on the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ISS Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan and Dr. William M. Mitchell&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-792791","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ISS Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan and Dr. William M. Mitchell - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ISS Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan and Dr. William M. Mitchell - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ISS Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan and Dr. William M. Mitchell ISS Finds That Activist Group\u2019s Plan is \u201cLimited\u201d and Does Not Justify Control of the Board ISS Notes Activist Group Nominee Robert L. Chioini \u201cDoes Not Appear to Be an Appropriate Choice for the AIM Board\u201d Given His Track Record at Rockwell Medical and Ties to Securities Law Felons ISS Also Recommends Against Election of Activist Group Nominee Todd A. Deutsch AIM Highlights $15 Million+ Investment Partnership Between Activist Group Nominees Ted Kellner and Paul Sweeney \u2013 Meaning They Are Not Independent of One Another Company Urges Shareholders to Safeguard AIM by Voting \u201cFOR\u201d ALL Four of the Board\u2019s Incumbent Candidates on the &hellip; Continue reading &quot;ISS Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan and Dr. William M. Mitchell&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-05T14:05:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241205465233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ISS Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan and Dr. William M. Mitchell\",\"datePublished\":\"2024-12-05T14:05:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\\\/\"},\"wordCount\":1672,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241205465233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\\\/\",\"name\":\"ISS Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan and Dr. William M. Mitchell - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241205465233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2024-12-05T14:05:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241205465233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20241205465233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ISS Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan and Dr. William M. Mitchell\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ISS Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan and Dr. William M. Mitchell - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\/","og_locale":"en_US","og_type":"article","og_title":"ISS Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan and Dr. William M. Mitchell - Market Newsdesk","og_description":"ISS Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan and Dr. William M. Mitchell ISS Finds That Activist Group\u2019s Plan is \u201cLimited\u201d and Does Not Justify Control of the Board ISS Notes Activist Group Nominee Robert L. Chioini \u201cDoes Not Appear to Be an Appropriate Choice for the AIM Board\u201d Given His Track Record at Rockwell Medical and Ties to Securities Law Felons ISS Also Recommends Against Election of Activist Group Nominee Todd A. Deutsch AIM Highlights $15 Million+ Investment Partnership Between Activist Group Nominees Ted Kellner and Paul Sweeney \u2013 Meaning They Are Not Independent of One Another Company Urges Shareholders to Safeguard AIM by Voting \u201cFOR\u201d ALL Four of the Board\u2019s Incumbent Candidates on the &hellip; Continue reading \"ISS Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan and Dr. William M. Mitchell\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-05T14:05:18+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241205465233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ISS Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan and Dr. William M. Mitchell","datePublished":"2024-12-05T14:05:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\/"},"wordCount":1672,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241205465233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\/","name":"ISS Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan and Dr. William M. Mitchell - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241205465233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2024-12-05T14:05:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241205465233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20241205465233r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/iss-recommends-aim-immunotech-shareholders-vote-for-company-nominees-nancy-k-bryan-and-dr-william-m-mitchell\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ISS Recommends AIM ImmunoTech Shareholders Vote \u201cFOR\u201d Company Nominees Nancy K. Bryan and Dr. William M. Mitchell"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/792791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=792791"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/792791\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=792791"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=792791"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=792791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}